文献速递心律失常心力衰竭与心肌病

无心力衰竭房颤患者利钠肽水平的预后意义

Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure.
PubMed 文献 · Heart · 2020-11-20

基于Fushimi AF Registry社区前瞻性队列,纳入1159例无心力衰竭的房颤患者,将BNP转换为NT-proBNP并按四分位数分组。中位随访5.0年,NT-proBNP水平与卒中/系统性栓塞、全因死亡和心衰住院发生率显著相关,且为独立预测因子。

要点

  • 无心衰房颤患者中位NT-proBNP为488 ng/L,高值者卒中/栓塞、死亡和心衰住院风险更高。
  • NT-proBNP经多因素校正后仍为不良结局的独立预测因子。
  • 利钠肽或可用于无心衰房颤患者的风险分层。

核心结论

  • NT-proBNP水平是无心力衰竭房颤患者不良结局的显著预后标志物,可能具有临床价值。

研究设计与样本

  • Fushimi AF Registry为日本京都Fushimi区社区前瞻性房颤患者调查。
  • 纳入无心力衰竭的房颤患者,使用入组时BNP(n=388)或NT-proBNP(n=771)数据,BNP按公式转换为NT-proBNP。
  • 共1159例患者,平均年龄72.1±10.2岁,中位CHA2DS2-VASc评分3,口服抗凝药处方671例(56%)。
  • 按NT-proBNP水平四分位数分组,比较背景和结局。

主要发现

  • 中位NT-proBNP水平为488(IQR 169-1015)ng/L。
  • NT-proBNP水平高的患者更年长、CHA2DS2-VASc评分更高且口服抗凝药处方更多(均p<0.001)。
  • 中位随访5.0年,Kaplan-Meier曲线显示NT-proBNP水平与卒中/系统性栓塞、全因死亡和心衰住院发生率显著相关(log rank,均p<0.001)。
  • 多变量Cox回归分析显示,经多种混杂因素校正后,NT-proBNP水平仍为不良结局的独立预测因子。

临床怎么用

  • 在无心力衰竭的房颤患者中,可检测NT-proBNP水平以辅助风险分层。
  • NT-proBNP水平较高的无心衰房颤患者可能需要更密切的随访和风险管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Natriuretic peptides are an important prognostic marker in patients with heart failure (HF). However, little is known regarding their prognostic significance in patients with atrial fibrillation (AF) without HF and natriuretic peptides levels are underused in these patients in daily practice. METHODS: The Fushimi AF Registry is a community-based prospective survey of patients with AF in Fushimi-ku, Kyoto, Japan. We investigated patients with AF without HF (defined as prior HF hospitalisation, New York Heart Association functional class≥2 or left ventricular ejection fraction<40%) using the data of B-type natriuretic peptide (BNP, n=388) or N-terminal pro-B-type natriuretic peptide (NT-proBNP, n=771) at enrolment. BNPs were converted to NT-proBNP using a conversion formula. We divided the patients according to quartiles of NT-proBNP levels and compared the backgrounds and outcomes. RESULTS: Of 1159 patients (mean age: 72.1±10.2 years, median CHA2DS2-VASc score: 3 and oral anticoagulant (OAC) prescription: 671 (56%)), the median NT-proBNP level was 488 (IQR 169-1015) ng/L. Patients with high NT-proBNP levels were older, had higher CHA2DS2-VASc scores and had more OAC prescription (all p<0.001). Kaplan-Meier curves demonstrated that NT-proBNP levels were significantly associated with higher incidences of stroke/systemic embolism, all-cause death and HF hospitalisation during a median follow-up period of 5.0 years (log rank, all p<0.001). Multivariable Cox regression analyses revealed that NT-proBNP levels were an independent predictor of adverse outcomes even after adjustment by various confounders. CONCLUSION: NT-proBNP levels are a significant prognostic marker for adverse outcomes in patients with AF without HF and may have clinical value. TRIAL REGISTRATION NUMBER: UMIN000005834.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Hamatani Y, Iguchi M, Ueno K, et al. Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. Heart. 2020. PMID: 33219109. doi:10.1136/heartjnl-2020-317735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。